NFKB1 and Hermansky-Pudlak syndrome: Thus, given the shared involvement of iNOS in mediating NFκB-mediated HPS and muscle wasting, any therapy that targets the iNOS-NO pathway may prove to be an effective therapeutic strategy in both diseased states2, 6, 11.